Teva Pharmaceutical Industries Ltd
F:TEV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Teva Pharmaceutical Industries Ltd
F:TEV
|
IL |
|
Puuilo Oyj
F:8JQ
|
FI |
|
Zegona Communications PLC
F:1ZG
|
UK |
|
Chandra Asri Petrochemical Tbk PT
IDX:TPIA
|
ID |
|
D
|
Deutsche Boerse AG
F:DB1
|
DE |
|
M
|
Manulife Financial Corp
SWB:MLU
|
CA |
|
C
|
Corning Inc
XHAM:GLW
|
US |
|
Komercni Banka as
PSE:KOMB
|
CZ |
|
N
|
Nexon Co Ltd
OTC:NEXOY
|
JP |
|
Jabil Inc
NYSE:JBL
|
US |
|
M
|
McKesson Corp
BMV:MCK
|
US |
|
Delta Lithium Ltd
ASX:DLI
|
AU |
|
B
|
British American Tobacco plc
DUS:BMT
|
UK |
|
Spotify Technology SA
LSE:0SPT
|
LU |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
US |
|
C
|
Credit Agricole SA
SWB:XCA
|
FR |
|
Q
|
Quest Diagnostics Inc
F:QDI
|
US |
|
J
|
Jiangxi Copper Co Ltd
SWB:JIX
|
CN |
|
T
|
Trupanion Inc
F:TPW
|
US |
|
A
|
American Water Works Company Inc
LSE:0HEW
|
US |
|
N
|
NEC Corp
DUS:NEC1
|
JP |
|
Resmed Inc
F:RMEA
|
US |
|
B
|
Bayer AG
SWB:BAYA
|
DE |
|
N
|
Nikon Corp
SWB:NKN
|
JP |
Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries is a global drug company best known for making generic medicines, which are lower-cost versions of branded drugs after patent protection ends. It also sells a smaller portfolio of branded specialty medicines, with a focus on treatments for the nervous system, breathing problems, and other chronic conditions. Its products are sold to pharmacies, hospitals, doctors, governments, and health systems around the world. Teva makes money mainly by selling finished medicines, either under its own name or through large-volume generic supply contracts. In generics, it competes on cost, manufacturing scale, and the ability to launch approved alternatives quickly when patents expire. In specialty drugs, it earns more from branded therapies that treat specific diseases and often require ongoing prescriptions. What makes Teva important in the drug industry is its role as a major supplier of affordable medicines. It sits between patent-based drug makers and the patients, insurers, and public health systems that need lower-priced alternatives. That mix of high-volume generics and selected branded treatments gives Teva a business model that depends on manufacturing strength, regulatory approvals, and broad distribution rather than a single blockbuster drug.
Teva Pharmaceutical Industries is a global drug company best known for making generic medicines, which are lower-cost versions of branded drugs after patent protection ends. It also sells a smaller portfolio of branded specialty medicines, with a focus on treatments for the nervous system, breathing problems, and other chronic conditions. Its products are sold to pharmacies, hospitals, doctors, governments, and health systems around the world.
Teva makes money mainly by selling finished medicines, either under its own name or through large-volume generic supply contracts. In generics, it competes on cost, manufacturing scale, and the ability to launch approved alternatives quickly when patents expire. In specialty drugs, it earns more from branded therapies that treat specific diseases and often require ongoing prescriptions.
What makes Teva important in the drug industry is its role as a major supplier of affordable medicines. It sits between patent-based drug makers and the patients, insurers, and public health systems that need lower-priced alternatives. That mix of high-volume generics and selected branded treatments gives Teva a business model that depends on manufacturing strength, regulatory approvals, and broad distribution rather than a single blockbuster drug.
Growth engines: Teva said AUSTEDO, AJOVY and UZEDY all had strong Q2 results, and management raised full-year revenue guidance for each of the three products.
Margins and cash: Revenue was stable despite the drag from generic REVLIMID, gross margin improved by 80 basis points, and free cash flow rose 31%.
Pipeline momentum: Management highlighted 8 major pipeline milestones this year, including olanzapine, ecopipane, DARI, celiac data and new TL1A indications.
Generics mixed: The generics business declined 15% year over year, but management said that excluding REVLIMID it was broadly stable and still capable of low single-digit long-term growth.
Balance sheet: Teva said Fitch upgraded it to investment grade and that net debt-to-EBITDA would have been 2.3x excluding the MLX deal, moving toward the 2x target by 2027.
Investor focus: Analysts pressed management on AUSTEDO payer dynamics ahead of 2027, celiac readout timing, biosimilars growth, and the impact of U.S. tariffs.